Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice

Eukaryotic protein production in designed storage organelles

(2012) Margarita Torrent et al.   BMC BIOLOGY

Emerging human papillomavirus vaccines

(2012) Barbara Ma et al.   EXPERT OPINION ON EMERGING DRUGS

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

(2011) A. Zimran et al.   BLOOD

Clinical Applications of DNA Vaccines: Current Progress

(2011) B. Ferraro et al.   CLINICAL INFECTIOUS DISEASES

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Plant-made vaccines for humans and animals

(2010) Edward P. Rybicki   PLANT BIOTECHNOLOGY JOURNAL

Protein production from recombinant protein bodies

(2010) Blanca Llompart et al.   PROCESS BIOCHEMISTRY

An E7-based therapeutic vaccine protects mice against HPV16 associated cancer

(2009) Aldo Venuti et al.   VACCINE

Therapeutic human papillomavirus vaccines: current clinical trials and future directions

(2008) Chien-Fu Hung et al.   EXPERT OPINION ON BIOLOGICAL THERAPY